NCT05454956Phase 2Completed

Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

Study sponsor: Tarsus Pharmaceuticals, Inc. · TARS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-05-18Actual
Enrollment · participants39Actual
Source updated2025-10-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview